Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 5,460,000 shares, an increase of 31.6% from the February 13th total of 4,150,000 shares. Based on an average daily volume of 772,500 shares, the short-interest ratio is presently 7.1 days. Currently, 6.9% of the company’s shares are short sold.
Insider Buying and Selling
In other news, insider Karen M. Anderson sold 10,624 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $17.32, for a total value of $184,007.68. Following the completion of the transaction, the insider now directly owns 71,525 shares of the company’s stock, valued at approximately $1,238,813. This trade represents a 12.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the completion of the transaction, the general counsel now directly owns 118,265 shares of the company’s stock, valued at approximately $1,808,271.85. This trade represents a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 275,605 shares of company stock valued at $4,643,570 in the last three months. Insiders own 11.59% of the company’s stock.
Institutional Trading of Centessa Pharmaceuticals
Several large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $31,000. GAMMA Investing LLC boosted its stake in Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the last quarter. Barclays PLC boosted its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $171,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Centessa Pharmaceuticals Stock Performance
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the company. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Morgan Stanley reissued an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $26.00.
Read Our Latest Analysis on CNTA
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Featured Articles
- Five stocks we like better than Centessa Pharmaceuticals
- How to Profit From Growth Investing
- How to Build the Ultimate Everything ETF Portfolio
- Most active stocks: Dollar volume vs share volume
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Pros And Cons Of Monthly Dividend Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.